WO2007110727A3 - Amide stabilized hydroxyethylamines - Google Patents

Amide stabilized hydroxyethylamines Download PDF

Info

Publication number
WO2007110727A3
WO2007110727A3 PCT/IB2007/000711 IB2007000711W WO2007110727A3 WO 2007110727 A3 WO2007110727 A3 WO 2007110727A3 IB 2007000711 W IB2007000711 W IB 2007000711W WO 2007110727 A3 WO2007110727 A3 WO 2007110727A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
hydroxyethylamines
amide
methods
stabilized
Prior art date
Application number
PCT/IB2007/000711
Other languages
French (fr)
Other versions
WO2007110727A2 (en
Inventor
Edward Fox Kleinman
Original Assignee
Pfizer Prod Inc
Edward Fox Kleinman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Edward Fox Kleinman filed Critical Pfizer Prod Inc
Publication of WO2007110727A2 publication Critical patent/WO2007110727A2/en
Publication of WO2007110727A3 publication Critical patent/WO2007110727A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Abstract

This invention pertains to amide and ester derivatives of hydroxyethylamine compounds that serve as effective beta-secretase inhibitors. The invention further relates to intermediates for preparation of such compounds; pharmaceutical compositions comprising such compounds; and, the use of such compounds in methods for treating certain central nervous system (CNS) disorders or conditions. The invention also relates to methods for treating neurodegenerative disorders, for example Alzheimer's disease.
PCT/IB2007/000711 2006-03-27 2007-03-15 Amide stabilized hydroxyethylamines WO2007110727A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74381206P 2006-03-27 2006-03-27
US60/743,812 2006-03-27

Publications (2)

Publication Number Publication Date
WO2007110727A2 WO2007110727A2 (en) 2007-10-04
WO2007110727A3 true WO2007110727A3 (en) 2007-12-06

Family

ID=38458183

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/000711 WO2007110727A2 (en) 2006-03-27 2007-03-15 Amide stabilized hydroxyethylamines

Country Status (1)

Country Link
WO (1) WO2007110727A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2913886B1 (en) 2007-03-22 2012-03-02 Guerbet Sa USE OF METAL NANOPARTICLES IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002512A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
WO2002002505A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
WO2003040096A2 (en) * 2001-11-08 2003-05-15 Elan Pharmaceuticals, Inc. N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives
WO2003072535A2 (en) * 2002-02-27 2003-09-04 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
WO2007047305A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002512A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
WO2002002505A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
WO2003040096A2 (en) * 2001-11-08 2003-05-15 Elan Pharmaceuticals, Inc. N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives
WO2003072535A2 (en) * 2002-02-27 2003-09-04 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
WO2007047305A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. DATTA ET AL: "A stereoselective route to hydroxyethylamine dipeptide isosteres", JOURNAL OF ORGANIC CHEMISTRY., vol. 65, no. 22, 2000, USAMERICAN CHEMICAL SOCIETY, WASHINGTON, DC., pages 7609 - 7611, XP002450069 *
D. NOETEBERG ET AL: "Design and synthesis of Plasmepsin I and Plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes", JOURNAL OF MEDICINAL CHEMISTRY., vol. 46, no. 5, 2003, USAMERICAN CHEMICAL SOCIETY. WASHINGTON., pages 734 - 746, XP002450067 *
J. GAO ET AL: "Transport characteristics of peptides and peptidomimetics: II. Hydroxyethylamine bioisostere-containing peptidomimetics as substrstes for the oligopeptide transporter andp-glycoprotein in the intestinal mucosa", JOURNAL OF PEPTIDE RESEARCH., vol. 57, no. 5, 2001, GBBLACKWELL PUBLISHING LTD., OXFORD., pages 361 - 373, XP002450068 *
MUTHAS ET AL: "Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 13, no. 18, 15 September 2005 (2005-09-15), pages 5371 - 5390, XP005021041, ISSN: 0968-0896 *
TUCKER T J ET AL: "A SERIES OF POTENT HIV-1 PROTEASE INHIBITORS CONTAINING A HYDROXYETHYL SECONDARY AMINE TRANSITION STATE ISOSTERE: SYNTHESIS ENZYME INHIBITION AND ANTIVIRAL ACTIVITY", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 35, no. 14, 1992, pages 2525 - 2533, XP001040621, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
WO2007110727A2 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
WO2007016155A3 (en) Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
IL196543A (en) Pyridazinone derivatives and pharmaceutical compositions comprising them for use in the treatment of disorders
WO2008062276A3 (en) Acetylene derivatives as stearoyl coa desaturase inhibitors
WO2007038610A3 (en) Use of natural products for treatment of neurological disorders
WO2008008551A3 (en) 2-substituted proline bis-amide orexin receptor antagonists
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007067511A3 (en) Morpholine carboxamide prokineticin receptor antagonists
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006072828A3 (en) Heteroaromatic quinoline compounds and their use as pde10 inhibitors
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006121560A3 (en) Methods and compositions for treatment of cns disorders
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006044497A3 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
IL197080A0 (en) Pyrimidone compounds as gsk-3 inhibitors
WO2008132139A3 (en) New heterocyclic derivatives useful for the treatment of cns disorders
WO2010079431A3 (en) Compounds for the prevention and treatment of cardiovascular disease
WO2007052023A3 (en) Novel compounds
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
EA200801184A1 (en) DERIVATIVES OF PIPEREDIN-4-IL-PYRIDAZIN-3-ILAMINE AS FAST DISCRETING ANTAGONISTS OF DOPAMINE 2 RECEPTOR
WO2006057945A3 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07713135

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07713135

Country of ref document: EP

Kind code of ref document: A2